News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
744,883 Results
Type
Article (44051)
Company Profile (468)
Press Release (700346)
Multimedia
Podcasts (139)
Webinars (23)
Section
Business (209452)
Career Advice (2051)
Deals (36193)
Drug Delivery (137)
Drug Development (84082)
Employer Resources (174)
FDA (16772)
Job Trends (15218)
News (354522)
Policy (33310)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2682)
Accelerated approval (48)
Adcomms (29)
Allergies (170)
Alliances (51114)
ALS (208)
Alzheimer's disease (1821)
Antibody-drug conjugate (ADC) (450)
Approvals (17092)
Artificial intelligence (656)
Autoimmune disease (255)
Automation (52)
Bankruptcy (374)
Best Places to Work (11841)
BIOSECURE Act (20)
Biosimilars (217)
Biotechnology (330)
Bladder cancer (187)
Brain cancer (72)
Breast cancer (726)
Cancer (5739)
Cardiovascular disease (476)
Career advice (1739)
Career pathing (43)
CAR-T (325)
CDC (56)
Celiac Disease (2)
Cell therapy (867)
Cervical cancer (44)
Clinical research (72399)
Collaboration (2096)
Company closure (4)
Compensation (1350)
Complete response letters (88)
COVID-19 (2795)
CRISPR (109)
C-suite (1094)
Cystic fibrosis (158)
Data (7550)
Decentralized trials (3)
Denatured (44)
Depression (168)
Dermatology (71)
Diabetes (566)
Diagnostics (6946)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (325)
Drug pricing (208)
Drug shortages (32)
Duchenne muscular dystrophy (289)
Earnings (92571)
Editorial (68)
Employer branding (21)
Employer resources (153)
Events (122662)
Executive appointments (1090)
FDA (20386)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (34)
Funding (1735)
Gene editing (235)
Generative AI (56)
Gene therapy (731)
GLP-1 (1081)
Government (4817)
Grass and pollen (6)
Guidances (403)
Healthcare (19301)
HIV (79)
Huntington's disease (54)
IgA nephropathy (97)
Immunology and inflammation (307)
Immuno-oncology (93)
Indications (168)
Infectious disease (3134)
Inflammatory bowel disease (216)
Inflation Reduction Act (17)
Influenza (137)
Intellectual property (283)
Interviews (319)
IPO (16946)
IRA (53)
Job creations (3717)
Job search strategy (1445)
JPM (67)
Kidney cancer (18)
Labor market (96)
Layoffs (592)
Leadership (39)
Legal (8031)
Liver cancer (100)
Longevity (31)
Lung cancer (766)
Lymphoma (422)
Machine learning (57)
Management (59)
Manufacturing (998)
MASH (187)
Medical device (14042)
Medtech (14128)
Mergers & acquisitions (20450)
Metabolic disorders (1501)
mRNA (215)
Multiple sclerosis (186)
NASH (20)
Neurodegenerative disease (417)
Neuropsychiatric disorders (110)
Neuroscience (3339)
Neurotech (1)
NextGen: Class of 2026 (6773)
Non-profit (4597)
Now hiring (75)
Obesity (718)
Opinion (308)
Ovarian cancer (208)
Pain (249)
Pancreatic cancer (287)
Parkinson's disease (366)
Partnered (34)
Patents (571)
Patient recruitment (645)
Peanut (62)
People (60866)
Pharmaceutical (80)
Pharmacy benefit managers (33)
Phase 1 (22770)
Phase 2 (31945)
Phase 3 (23583)
Pipeline (7777)
Policy (324)
Postmarket research (2604)
Preclinical (9765)
Press Release (67)
Prostate cancer (293)
Psychedelics (61)
Radiopharmaceuticals (336)
Rare diseases (1088)
Real estate (6073)
Recruiting (71)
Regulatory (25714)
Reports (55)
Research institute (2510)
Resumes & cover letters (356)
Rett syndrome (34)
RNA editing (24)
RSV (88)
Schizophrenia (178)
Series A (290)
Series B (218)
Service/supplier (11)
Sickle cell disease (116)
Special edition (27)
Spinal muscular atrophy (170)
Sponsored (47)
Startups (3823)
State (2)
Stomach cancer (19)
Supply chain (129)
Tariffs (88)
The Weekly (92)
Vaccines (1105)
Venture capital (109)
Weight loss (467)
Women's health (121)
Worklife (21)
Date
Last 7 days (773)
Last 30 days (2731)
Last 365 days (31074)
2026 (10109)
2025 (31062)
2024 (36290)
2023 (41014)
2022 (52277)
2021 (56762)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32347)
2015 (38397)
2014 (32185)
2013 (27109)
2012 (29222)
2011 (29865)
2010 (27992)
Location
Africa (757)
Alabama (97)
Alaska (7)
Arizona (349)
Arkansas (16)
Asia (41059)
Australia (6836)
California (12887)
Canada (3659)
China (1332)
Colorado (554)
Connecticut (567)
Delaware (384)
Europe (90248)
Florida (1907)
Georgia (412)
Hawaii (3)
Idaho (62)
Illinois (1030)
India (88)
Indiana (584)
Iowa (25)
Japan (519)
Kansas (133)
Kentucky (49)
Louisiana (40)
Maine (75)
Maryland (1549)
Massachusetts (9309)
Michigan (353)
Minnesota (704)
Mississippi (6)
Missouri (145)
Montana (35)
Nebraska (29)
Nevada (137)
New Hampshire (89)
New Jersey (3425)
New Mexico (31)
New York (3378)
North Carolina (1695)
North Dakota (9)
Northern California (6391)
Ohio (381)
Oklahoma (23)
Oregon (44)
Pennsylvania (2586)
Puerto Rico (28)
Rhode Island (51)
South America (1126)
South Carolina (85)
South Dakota (2)
Southern California (5053)
Tennessee (204)
Texas (2032)
United States (45742)
Utah (384)
Vermont (1)
Virginia (307)
Washington D.C. (81)
Washington State (1058)
West Virginia (4)
Wisconsin (127)
Wyoming (2)
744,883 Results for "rapt therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
·
1 min read
Press Releases
RAPT Therapeutics to Participate in Multiple Upcoming November 2025 Investor Conferences
November 4, 2025
·
1 min read
Press Releases
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
October 21, 2025
·
4 min read
Press Releases
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
October 22, 2025
·
4 min read
Press Releases
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 7, 2025
·
9 min read
Mergers & acquisitions
GSK Picks Up RAPT for $2.2B as Miels Makes First Move as CEO
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, potentially setting up a competition for GSK with Roche’s Xolair.
January 20, 2026
·
2 min read
·
Tristan Manalac
Press Releases
RAPT Therapeutics to Participate in Multiple Upcoming September 2025 Investor Conferences
August 28, 2025
·
1 min read
Press Releases
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
October 28, 2025
·
7 min read
Press Releases
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
August 8, 2025
·
7 min read
Press Releases
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
October 19, 2025
·
3 min read
1 of 74,489
Next
